Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

(b) Resignations of Eric Aguiar and Robert Repella as Members of the Board of Directors

On January 31, 2020, each of Eric Aguiar and Robert Repella, members of the Board of Directors (the "Board") of Biohaven Pharmaceutical Holding Company Ltd. (the "Company"), notified the Company of his intent to resign from the Board, effective immediately. Each of Dr. Aguiar's and Mr. Repella's decisions to resign from the Board was not as a result of any disagreement with the Company or the Board. Mr. Repella will continue his relationship with the Company as a consultant.

(d) Appointment of Michael T. Heffernan as Member of the Board of Directors

On January 31, 2020, the Board appointed Michael T. Heffernan as a director to fill the vacancy created by the resignation of Robert Repella described above. Mr. Heffernan will serve in the class of directors whose term will expire at the Company's 2021 Annual Meeting of Shareholders. Mr. Heffernan has also been appointed as a member and the chair of the Compensation Committee of the Board and a member of the Nominating and Governance Committee of the Board. There is no arrangement or understanding between Mr. Heffernan and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Heffernan and any of the Company's other directors or executive officers.

In accordance with the Company's compensation policy for non-employee directors, on January 31, 2020, Mr. Heffernan was granted an option to purchase 36,000 shares of the Company's common shares at an exercise price of $48.49 per share, the closing price of the Company's common shares on the date of grant. The shares underlying this option will vest in three annual installments on each of January 31, 2021, January 31, 2022 and January 31, 2023, subject to Mr. Heffernan's continuous service through each vesting date. Additionally, Mr. Heffernan will be entitled to receive a $35,000 annual retainer for his service as a director and aggregate annual fees of $13,750 for his service as a member and the chair of the Compensation Committee and as a member of the Nominating and Governance Committee.

Item 7.01 Regulation FD Disclosure.

On January 31, 2020, the Company issued a press release announcing Mr. Heffernan's appointment to the Board, the resignations of Dr. Aguiar and Mr. Repella and certain other changes to the composition of the Board's committees. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report.

The information in set forth in this Item 7.01 and in Exhibit 99.1 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.






(d)    Exhibits



Exhibit No.    Exhibit Description

   99.1          Press Release, dated January 31, 2020, "Biohaven Appoints Michael T
               Heffernan to Board of Directors."

    101        Pursuant to Rule 406 of Regulation S-T, the cover page information is
               formatted in iXBRL (Inline eXtensible Business Reporting Language).

    104        Cover Page Interactive Data File (formatted in iXBRL in Exhibit 101).

© Edgar Online, source Glimpses